No Data
Olema Pharmaceuticals Insiders Sell US$1.6m Of Stock, Possibly Signalling Caution
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29
Capital One Financial Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $26
Promising Potential of Olema Pharmaceuticals' Palazestrant and KAT6 Inhibitor Fuels Buy Rating
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy
President Sean Bohen Sold A Bunch Of Shares In Olema PharmaceuticalsNo Data
No Data
